Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dapagliflozin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    145 result(s) found for: Dapagliflozin. Displaying page 3 of 8.
    « Previous 1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2014-003432-39 Sponsor Protocol Number: D1690L00016 Start Date*: 2014-11-19
    Sponsor Name:Dept of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University
    Full Title: A 24-week, single centre, randomized, parallel-group, double-blind, placebo controlled Phase II study to evaluate the efficacy on body weight of dapagliflozin 10 mg once daily in combination with e...
    Medical condition: Obesity defined as body mass index (BMI) 30-45 kg/m2 Obesity related metabolic disorders
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004861 10029885 Obesity, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003175-34 Sponsor Protocol Number: DAPARHT Start Date*: 2022-02-09
    Sponsor Name:Oslo University Hospital
    Full Title: DAPARHT: DAPAgliflozin for Renal protection in Heart Transplant recipients
    Medical condition: heart transplant recipients in follow-up
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-000679-18 Sponsor Protocol Number: CV181-169 Start Date*: 2012-11-13
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Add-On Therapy with Saxagliptin and Dapagliflozin added to Metformin...
    Medical condition: Type 2 Diabetes who have Inadequate Glycemic Control on Metformin Alone
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-002893-20 Sponsor Protocol Number: 2021/0188/HP Start Date*: 2021-12-03
    Sponsor Name:CHU de Rouen
    Full Title: Impact of dapagliflozin on vascular function in chronic kidney disease patients
    Medical condition: chronic kidney disease patients
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004929-23 Sponsor Protocol Number: 2020/1002 Start Date*: 2021-04-14
    Sponsor Name:University Medical Center Groningen
    Full Title: Individual albuminuria lowering response to dapagliflozin in a decentralized clinical trial in patients with type 2 diabetes mellitus and elevated albuminuria
    Medical condition: Patients with type 2 diabetes and albuminuria >20 mg/g (2.26 mg/mmol)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002212-41 Sponsor Protocol Number: ESR-15-11453 Start Date*: 2016-12-06
    Sponsor Name:Stiftung Hannoversche Kinderheilanstalt, Kinder - und Jugendkrankenhaus AUF DER BULT, Diabeteszentrum für Kinder - und J
    Full Title: A Randomized, Double-Blind, Placebo-controlled, Single-center Phase 1 Inpatient Pilot Study to Explore the Safety and Efficacy of DAPAglifozin as Add-on to day and night closed-loop control using t...
    Medical condition: Type 1 Diabetes mellitus
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002614-12 Sponsor Protocol Number: ESR-17-13447(DAPA-HF) Start Date*: 2019-02-08
    Sponsor Name:Instituto de Investigación Sanitaria INCLIVA
    Full Title: Short-term Effects of Dapagliflozin on Peak VO2 in Patients with Heart Failure with Reduced Ejection Fraction and Type 2 Diabetes
    Medical condition: Stable symptomatic heart failure with reduced ejection fraction (HFrEF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10019280 Heart failures HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004723-31 Sponsor Protocol Number: ESR-14-10145 Start Date*: 2016-02-05
    Sponsor Name:UNIVERSITÀ CAMPUS BIO-MEDICO DI ROMA
    Full Title: Proof of concept study, a randomized, controlled, open and prospective period of one year to evaluate the effectiveness of treatment with saxagliptin / dapagliflozin + metformin vs insulin glargine...
    Medical condition: LADA
    Disease: Version SOC Term Classification Code Term Level
    21.0 10027433 - Metabolism and nutrition disorders 10066389 Latent autoimmune diabetes in adults PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003442-16 Sponsor Protocol Number: D169EC00002 Start Date*: 2019-04-17
    Sponsor Name:AstraZeneca AB
    Full Title: An International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients wi...
    Medical condition: Heart Failure Patients with Reduced Ejection Fraction (HFrEF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10078289 Heart failure with reduced ejection fraction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-005140-41 Sponsor Protocol Number: Saxa-Dapa1 Start Date*: 2017-05-10
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
    Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, PARALLEL-GROUP, SINGLE CENTER PILOT STUDY OF THE ACUTE AND CHRONIC EFFECTS OF DAPAGLIFLOZIN PLUS SAXAGLIPTIN IN ADDITION TO METFORMIN VERSUS...
    Medical condition: Patients with type 2 diabetes poorly controlled with metformin
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    23.0 10027433 - Metabolism and nutrition disorders 10012607 Diabetes mellitus inadequate control PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001262-35 Sponsor Protocol Number: D1690C00078 Start Date*: 2023-02-09
    Sponsor Name:The Brigham and Women's Hospital, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Trial to Evaluate the Effect of In-Hospital Initiation of Dapagliflozin on Clinical Outcomes in Patients Who Have Been St...
    Medical condition: The study is evaluating the effect of In-hospital initiation of dapagliflozin in patients who have been stabilized during hospitalization for Acute Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10000803 Acute heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-006577-30 Sponsor Protocol Number: D4326C00003 Start Date*: 2022-09-21
    Sponsor Name:AstraZeneca AB
    Full Title: A Two Part Phase IIa/b Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose-ranging Study to Assess Efficacy, Safety, and Tolerability of the Combination of Zibotentan and...
    Medical condition: Liver cirrhosis with features of portal hypertension.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10024667 Liver cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) AT (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004042-42 Sponsor Protocol Number: DEER Start Date*: 2014-06-19
    Sponsor Name:King’s College London [...]
    1. King’s College London
    2. Guy's and St Thomas NHS Foundation Trust
    Full Title: A study to investigate the potential renoprotective role of sodium-glucose transporter-2 (SGLT-2) antagonist Dapagliflozin in Type 2 diabetic patients with diabetic nephropathy
    Medical condition: Diabetic Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-003911-21 Sponsor Protocol Number: 23092017 Start Date*: 2018-05-11
    Sponsor Name:University of Oxford
    Full Title: Dapagliflozin during exercise for the prevention of hypoglycaemia in Type 1 diabetes
    Medical condition: Type 1 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2020-001247-12 Sponsor Protocol Number: 20-001 Start Date*: 2021-03-30
    Sponsor Name:University Medical Center Groningen
    Full Title: An Open Label, Phase IV, Mechanistic, Study to Evaluate the Natriuretic Effect of 2-Week Dapagliflozin treatment in Type 2 Diabetes Mellitus Patients with Impaired Renal Function
    Medical condition: Type 2 diabetes mellitus (T2DM) with impaired renal function
    Disease: Version SOC Term Classification Code Term Level
    23.0 10027433 - Metabolism and nutrition disorders 10012607 Diabetes mellitus inadequate control PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000973-26 Sponsor Protocol Number: SOGALDI-PEF Start Date*: 2022-06-01
    Sponsor Name:Faculdade de Medicina da Universidade do Porto
    Full Title: SOdium-Glucose cotransporter 2 inhibitor, ALDosterone AntagonIst, or both for heart failure with Preserved Ejection Fraction: a two-centre randomised three-treatment three-period crossover trial
    Medical condition: Heart Failure with Preserved Ejection Fraction
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004849 10076396 Heart failure with preserved ejection fraction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002231-26 Sponsor Protocol Number: D1693C00005 Start Date*: 2011-09-29
    Sponsor Name:AstraZeneca AB
    Full Title: A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, International Phase III Study with a 28-week Extension Period to Evaluate the Safety and Efficacy of Dapagliflozin 10mg once da...
    Medical condition: Type II diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10012613 Diabetes mellitus non-insulin-dependent LLT
    Population Age: Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) SK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-005931-27 Sponsor Protocol Number: D1690C00005 Start Date*: 2008-04-17
    Sponsor Name:AstraZeneca AB
    Full Title: A 24-Week Randomised, Double-blind, Parallel-group, Multi-centre, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Dapagliflozin in Combination with Glimepiride (a Sulphony...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029505 Non-insulin-dependent diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2014-002370-36 Sponsor Protocol Number: 49690 Start Date*: 2015-02-26
    Sponsor Name:Slotervaart Hospital
    Full Title: Randomized, double-blind, placebo-controlled trial of the effectiveness and safety of dapagliflozin on blood glucose control during glucocorticoid treatment for acute exacerbation COPD
    Medical condition: Glucocorticoid induced hyperglycemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-000979-16 Sponsor Protocol Number: ESR-17-12784 Start Date*: 2019-08-21
    Sponsor Name:Dr. Guillem Cuatrecasas - CPEN S.L.
    Full Title: Dapagliflozin effect in the reduction of different abdominal fat layers in type 2 diabetic patients.
    Medical condition: Abdominal fat layers in type 2 diabetic patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 28 23:48:22 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA